HCT Using Treosulfan for Bone Marrow Failure Diseases (BMT CTN 1904)
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter phase II study designed to evaluate the outcomes of
patients with bone marrow failure diseases (BMFD) undergoing HLA-matched related, HLA-matched
unrelated, or single HLA-class 1 allele or HLA-DQB1 antigen or allele mismatched unrelated
hematopoietic cell transplantation (HCT) using treosulfan-based conditioning.
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Marrow Donor Program